Revvity initiated with an Equal Weight at Wells Fargo

Wells Fargo initiated coverage of Revvity with an Equal Weight rating and $95 price target. The firm sees opportunity for Revvity to accelerate growth across its Life Science & Diagnostics markets, but remains cautious near-term due to potential volatility around post-spin operations and pharma/biotech headwinds.